200204-85-9

Basic information

• Product Name: ethyl 2-(5-bromobenzofuran-3-yl)acetate
• Synonyms: 5-bromo-3-Benzofuranacetic acid ethyl ester;Ethyl 2-(5-bromobenzofuran-3-yl);ethyl 2-(5-bromobenzofuran-3-yl)acetate
• CAS NO: 200204-85-9
• Molecular Formula: C12H11BrO3
• Molecular Weight: 283.12
• Product Categories: CHIRAL CHEMICALS
• Mol File: 200204-85-9.mol

Chemical Properties

• Boiling Point: 341.683 °C at 760 mmHg
• Flash Point: 160.445 °C
• Appearance: /
• Density: 1.476 g/cm³
• Vapor Pressure: 7.91E-05mmHg at 25°C
• Refractive Index: 1.589
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: ethyl 2-(5-bromobenzofuran-3-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(5-bromobenzofuran-3-yl)acetate(200204-85-9)
• EPA Substance Registry System: ethyl 2-(5-bromobenzofuran-3-yl)acetate(200204-85-9)

Safety Data

• Hazardous Substances Data: 200204-85-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Ethyl 2-(5-bromobenzofuran-3-yl)acetate is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its specific structural features and reactivity contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, ethyl 2-(5-bromobenzofuran-3-yl)acetate serves as a crucial component in the production of pesticides and other agrochemicals. Its properties enable the creation of effective compounds for crop protection and enhancement of agricultural yields.
Used in Organic Chemistry Research and Development:
Ethyl 2-(5-bromobenzofuran-3-yl)acetate is employed as a versatile building block in organic chemistry. Its unique structure and reactivity make it an essential tool for researchers in the development of novel chemical reactions and the synthesis of complex organic molecules.

InChI:InChI=1/C12H11BrO3/c1-2-15-12(14)5-8-7-16-11-4-3-9(13)6-10(8)11/h3-4,6-7H,2,5H2,1H3

Upstream product

• 54450-20-3 5-bromo-3(2H)-benzofuranone 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 
• 106-41-2 4-bromo-phenol 
• 100959-21-5 2-hydroxy-5-bromophenacyl chloride 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 64-17-5 ethanol 

Relevant articles and documents

Synthesis and preliminary evaluation of benzofuran-oxadiazole conjugates as potential antitubercular agents

In the present study, a series of benzofuran-oxadiazole conjugates 7(a-o) was designed, synthesized and characterized through IR,1H NMR,13C NMR and mass spectral data. All the compounds were screened for preliminary antitubercular activity against Mycobacterium phlei and Mycobacterium tuberculosis H37RV. Among all the target compounds, the compound possessing chlorine (7k, MIC 1.56 μg/mL) and bromine (7m, MIC 1.56 μg/mL) on 6th position of benzofuran showed highest activity against Mycobacterium phlei. Whereas, bromine on either 5th position (7l, MIC 3.125 μg/mL) or 6th position (7m MIC 3.125 μg/mL) on benzofuran exhibited highest activity for Mycobacterium tuberculosis (H37 RV).

Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. Possible new GSK-3β therapies for bipolar disorders

More than two million American adults, or approximately one percent of the population 18 years or older, suffer from bipolar disorder. Current treatments include the so-called "mood stabilizers," lithium and valproic acid. Both are relatively dated drugs that are only partially effective and produce various undesirable side effects including weight gain. Based upon continued efforts to understand the molecular target for lithium, it now appears that specific inhibitors of the enzyme glycogen synthase kinase-3β (GSK-3β) may mimic the therapeutic action of mood stabilizers and might therefore allow for the design of improved drugs for treating patients with bipolar disorder as well as certain neurodegenerative disorders. Furthermore, the pro-apoptotic properties of the GSK-3 enzyme suggest the possible use of such inhibitors as neuroprotective agents. In fact, neuroprotection may contribute to the treatment of mood disorders. The present chemistry, modeling, and biology efforts have identified 3-benzofuranyl-4-indolylmaleimides as potent and relatively selective GSK-3β inhibitors. The best ligand in this series (having a Ki value of 4.6 nM against GSK-3β) was studied in a novel mouse model of mania that has recently been validated with several clinically effective mood stabilizers. This study presents the first demonstration of the efficacy of a GSK-3β inhibitor in this mouse model of mania. Selective brain penetrable GSK-3 ligands like those described herein become valuable research tools in better defining the role of this multifaceted kinase in both physiological and pathophysiological events.

Azetidine, pyrrolidine and piperidine derivatives as 5-HT1D receptor agonists

PCT No. PCT/GB97/01330 Sec. 371 Date Oct. 26, 1998 Sec. 102(e) Date Oct. 26, 1998 PCT Filed May 15, 1997 PCT Pub. No. WO97/45426 PCT Pub. Date Dec. 4, 1997A class of substituted azetidine, pyrrolidine and piperidine derivatives of Formula I are selective

Piperazine, piperidine and tetrahydropyridine derivatives as 5-HT receptor agonists

A class of N-substituted piperazine, piperidine, and tetrahydropyridine derivatives, further subltitutedat the 4-position by an optionally substituted alkenyl, alkynyl, aryl-alkyl or heteroaryl-alkyl moiety, are selective agonists of 5-HT 1 -like receptors, being potent agonists of the human 5-HT 1Dα receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT 1Dα receptor subtype relative to the 5-HT 1Dβ subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT 1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT 1D receptor agonists.